Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more
Time Frame | RLAY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.33% | -0.94% | -2.6% |
1-Month Return | -10.7% | -5.08% | -1.08% |
3-Month Return | -41.59% | -10.62% | 3.45% |
6-Month Return | -37.1% | -6.18% | 8.57% |
1-Year Return | -62.2% | 1.98% | 24.3% |
3-Year Return | -87.01% | -0.93% | 25.58% |
5-Year Return | -87.62% | 33.84% | 84.07% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 82.65M | 3.03M | 1.38M | 25.55M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.66,"profit":true},{"date":"2022-12-31","value":1.67,"profit":true},{"date":"2023-12-31","value":30.91,"profit":true}] |
Cost of Revenue | 2.85M | 3.55M | 3.92M | 4.13M | 5.27M | [{"date":"2019-12-31","value":54,"profit":true},{"date":"2020-12-31","value":67.36,"profit":true},{"date":"2021-12-31","value":74.49,"profit":true},{"date":"2022-12-31","value":78.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (2.85M) | 79.11M | (896.00K) | (2.75M) | 20.28M | [{"date":"2019-12-31","value":-3.6,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-1.13,"profit":false},{"date":"2022-12-31","value":-3.48,"profit":false},{"date":"2023-12-31","value":25.63,"profit":true}] |
Gross Margin | - | 95.71% | (29.58%) | (199.06%) | 79.37% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-30.91,"profit":false},{"date":"2022-12-31","value":-207.99,"profit":false},{"date":"2023-12-31","value":82.94,"profit":true}] |
Operating Expenses | 84.05M | 138.45M | 230.04M | 312.33M | 398.55M | [{"date":"2019-12-31","value":21.09,"profit":true},{"date":"2020-12-31","value":34.74,"profit":true},{"date":"2021-12-31","value":57.72,"profit":true},{"date":"2022-12-31","value":78.37,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (84.05M) | (55.80M) | (364.70M) | (299.27M) | (373.00M) | [{"date":"2019-12-31","value":-8404800000,"profit":false},{"date":"2020-12-31","value":-5579600000,"profit":false},{"date":"2021-12-31","value":-36469800000,"profit":false},{"date":"2022-12-31","value":-29927500000,"profit":false},{"date":"2023-12-31","value":-37300000000,"profit":false}] |
Total Non-Operating Income/Expense | 17.54M | 6.78M | 1.66M | 17.55M | 62.07M | [{"date":"2019-12-31","value":28.26,"profit":true},{"date":"2020-12-31","value":10.93,"profit":true},{"date":"2021-12-31","value":2.67,"profit":true},{"date":"2022-12-31","value":28.28,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (75.31M) | (52.41M) | (363.87M) | (290.51M) | (341.97M) | [{"date":"2019-12-31","value":-7530500000,"profit":false},{"date":"2020-12-31","value":-5241200000,"profit":false},{"date":"2021-12-31","value":-36387200000,"profit":false},{"date":"2022-12-31","value":-29050900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false}] |
Income Taxes | (8.80M) | (3.40M) | 132.94M | (36.25M) | (37.47M) | [{"date":"2019-12-31","value":-6.62,"profit":false},{"date":"2020-12-31","value":-2.56,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-27.27,"profit":false},{"date":"2023-12-31","value":-28.18,"profit":false}] |
Income After Taxes | (66.50M) | (49.01M) | (496.81M) | (254.26M) | (304.51M) | [{"date":"2019-12-31","value":-6650400000,"profit":false},{"date":"2020-12-31","value":-4901200000,"profit":false},{"date":"2021-12-31","value":-49680800000,"profit":false},{"date":"2022-12-31","value":-25425900000,"profit":false},{"date":"2023-12-31","value":-30450600000,"profit":false}] |
Income From Continuous Operations | (75.31M) | (52.41M) | (363.87M) | (290.51M) | (341.97M) | [{"date":"2019-12-31","value":-7530500000,"profit":false},{"date":"2020-12-31","value":-5241200000,"profit":false},{"date":"2021-12-31","value":-36387200000,"profit":false},{"date":"2022-12-31","value":-29050900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (66.50M) | (49.01M) | (496.81M) | (254.26M) | (341.97M) | [{"date":"2019-12-31","value":-6650400000,"profit":false},{"date":"2020-12-31","value":-4901200000,"profit":false},{"date":"2021-12-31","value":-49680800000,"profit":false},{"date":"2022-12-31","value":-25425900000,"profit":false},{"date":"2023-12-31","value":-34197300000,"profit":false}] |
EPS (Diluted) | - | (6.26) | (3.85) | (2.60) | (2.80) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-626,"profit":false},{"date":"2021-12-31","value":-385,"profit":false},{"date":"2022-12-31","value":-260,"profit":false},{"date":"2023-12-31","value":-280,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RLAY | |
---|---|
Cash Ratio | 17.88 |
Current Ratio | 18.42 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RLAY | |
---|---|
ROA (LTM) | -26.87% |
ROE (LTM) | -42.69% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RLAY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.10 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.90 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RLAY | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 69.59 |
P/B | 0.83 |
Price/FCF | NM |
EV/R | 18.17 |
EV/Ebitda | NM |
Relay Therapeutics Inc (RLAY) share price today is $4.34
Yes, Indians can buy shares of Relay Therapeutics Inc (RLAY) on Vested. To buy Relay Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RLAY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Relay Therapeutics Inc (RLAY) via the Vested app. You can start investing in Relay Therapeutics Inc (RLAY) with a minimum investment of $1.
You can invest in shares of Relay Therapeutics Inc (RLAY) via Vested in three simple steps:
The 52-week high price of Relay Therapeutics Inc (RLAY) is $12.14. The 52-week low price of Relay Therapeutics Inc (RLAY) is $4.11.
The price-to-earnings (P/E) ratio of Relay Therapeutics Inc (RLAY) is
The price-to-book (P/B) ratio of Relay Therapeutics Inc (RLAY) is 0.83
The dividend yield of Relay Therapeutics Inc (RLAY) is 0.00%
The market capitalization of Relay Therapeutics Inc (RLAY) is $696.31M
The stock symbol (or ticker) of Relay Therapeutics Inc is RLAY